Company Directory - CRISPR Therapeutics AG
Company Details - CRISPR Therapeutics AG
CRISPR Therapeutics AG
WebsiteZug, Switzerland
ISIN: CH0451161346
Biotechnology company focused on developing transformative medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.
CCI Score
CCI Score: CRISPR Therapeutics AG
22.95
-0.01%
Latest Event
Commitment to Corporate Responsibility and DEI Initiatives
CRISPR Therapeutics' Corporate Responsibility page emphasizes its commitment to diversity, equity, and inclusion as a core element of its ethical business practices. This focus indicates a positive stance on worker rights and corporate transparency, important factors in opposing authoritarian tendencies.
Take Action
So what can you do? Support CRISPR Therapeutics by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
SABOTEUR
CRISPR Therapeutics AG is currently rated as a Saboteur.
Latest Events
- JAN012025
CRISPR Therapeutics' Corporate Responsibility page emphasizes its commitment to diversity, equity, and inclusion as a core element of its ethical business practices. This focus indicates a positive stance on worker rights and corporate transparency, important factors in opposing authoritarian tendencies.
+80
Business Practices and Ethical Responsibility
January 1
The article from CRISPR Therapeutics details the company’s effort to uphold high corporate responsibility standards through diversity, equity, and inclusion initiatives. This positive emphasis on ethical business practices and inclusive workplace culture contributes to a strong score in the Business Practices and Ethical Responsibility category. Nevertheless, the lack of detail on broader labor rights metrics or supply chain ethics means there's some room for improvement in fully aligning with all criteria against fascism and authoritarian practices.
- OCT012023
Based on the article 'How to Combat Forced Labor in Supply Chains', this evaluation examines best practices for ethical sourcing and the elimination of forced labor in supply chains. No specific evidence was found linking CRISPR Therapeutics AG to forced labor issues, resulting in a neutral assessment.
+0
Supply Chain Ethics
March 21
The article discusses strategies to eliminate forced labor in supply chains, a key element under Supply Chain Ethics within Business Practices and Ethical Responsibility. However, there is no specific evidence suggesting that CRISPR Therapeutics AG engages in or combats forced labor practices in its supply chain. As a result, a neutral score is assigned in this category.
- DEC312022
In 2022, CRISPR Therapeutics spent $330,000 on lobbying efforts, a maneuver that raises concerns over its intent to influence political decision-making and potentially support policies aligned with authoritarian interests.
-40
Political Contributions and Lobbying Efforts
March 21
CRISPR Therapeutics' reported lobbying expenditure of $330,000 in 2022 points to a deliberate effort to influence political processes. From a left-leaning anti-fascist perspective, such expenditure is seen as contributing to corporate complicity in undermining democratic accountability by shaping policy in favor of authoritarian agendas.
Alternatives
Cambridge, United States
-13.08
Corporation
0.00
Beijing, China
0.00
_0.png?VersionId=E54j6B2ssY0mos4wxJcXCOh7Hall1IAR)
New York, United States
-1.65
Corporation
27.23
Corporation
9.63
Corporation
0.00
Corporation
0.00
Corporation
0.00
Corporation
0.00
Industries
- 325414
- Biological Product (except Diagnostic) Manufacturing
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)
- 621511
- Medical Laboratories